Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | - | - |
Min SIP Amount | ₹1000 | - |
Expense Ratio | 2.38 | - |
NAV | ₹15.45 | - |
Fund Started | 27 Jun 2023 | - |
Fund Size | ₹439.55 Cr | - |
Exit Load | Exit load of 1%, if redeemed within 15 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 29.42% | - |
3 Year | - | - |
5 Year | - | - |
1 Year
3 Year
5 Year
Equity | 98.97% | - |
Cash | -0.09% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Aster DM Healthcare Ltd. | 8.02% |
RPG Life Sciences Ltd. | 7.72% |
HFCL Ltd. | 7.02% |
Pfizer Ltd. | 6.93% |
Reliance Industries Ltd. | 6.91% |
Aurobindo Pharma Ltd. | 6.24% |
Sequent Scientific Ltd. | 6.23% |
Zydus Lifesciences Ltd. | 6.19% |
Glenmark Life Sciences Ltd. | 6.07% |
Ipca Laboratories Ltd. | 6.00% |
Name | Ankit A Pande | - |
Start Date | 22 Aug 2023 | - |
Name
Start Date
Description | The scheme seeks to long term capital appreciation by investing in equity/equity related instruments of companies from the healthcare sector. However, there is no assurance or guarantee that the investment objective of the Scheme will be achieved. The Scheme does not assure or guarantee any returns. | - |
Launch Date | 27 Jun 2023 | - |
Description
Launch Date